Recommendations from Experts in the Management of Adverse Reactions
to ALK Inhibitors (2021 Version).
10.3779/j.issn.1009-3419.2021.102.32
- Author:
Ke WANG
1
;
Juan LI
2
;
Jianguo SUN
3
;
Li LI
4
;
Xi ZHANG
5
;
Jianyong ZHANG
6
;
Min YU
7
;
Xianwei YE
8
;
Ming ZHANG
9
;
Yu ZHANG
10
;
Wenxiu YAO
2
;
Meijuan HUANG
7
Author Information
1. Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
2. Department of Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
3. Department of Oncology, Xinqiao Hospital, Army Military Medical University, Chongqing 400037, China.
4. Department of Respiratory and Critical Care Medicine, Army Special Medical Center (Daping Hospital), Chongqing 400042, China.
5. Department of Oncology, Chengdu Third People's Hospital, Chengdu 610000, China.
6. Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
7. Department of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
8. Department of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang 550002, China.
9. Department of Radiation Therapy, Yunnan Cancer Hospital, Kunming 650118, China.
10. Department of Oncology, Guizhou Provincial People's Hospital, Guiyang 550002, China.
- Publication Type:Journal Article
- Keywords:
Adverse reactions;
Anaplastic lymphoma kinase inhibitors;
Lung neoplasms;
Recommendations
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Crizotinib;
Humans;
Lung Neoplasms/genetics*;
Protein Kinase Inhibitors/adverse effects*;
Receptor Protein-Tyrosine Kinases/antagonists & inhibitors*
- From:
Chinese Journal of Lung Cancer
2021;24(12):815-828
- CountryChina
- Language:Chinese
-
Abstract:
Anaplastic lymphoma kinase (ALK) fusion gene, as a tumor driver gene, was crucial for the occurrence and development of non-small cell lung cancer (NSCLC). Recently, targeted ALK fusion gene has become the main treatment method for ALK-positive NSCLC. The first and second generation ALK inhibitors (ALKi), such as crizotinib, ceritinib, alectinib and ensartinib have been approved in China. However, there was no guidance for the management of ALKi adverse reactions. Therefore, this "Recommendations from experts in the management of adverse reactions to ALK inhibitors (2021 version)" has been summarized, led by Lung Cancer Professional Committee of Sichuan Cancer Society and Sichuan Medical Quality Control Center for Tumor Diseases, to provide practical and feasible strategies for clinical ALKi management specification of adverse reactions.
.
